The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma.
Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.
Uy
Geoffrey L
GL
Tomasson
Michael H
MH
Ruddell
Alisa
A
DiPersio
John F
JF
Vij
Ravi
R
D000227:Adenine Nucleotides / Q000008:administration & dosage* / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D001087:Arabinonucleosides / Q000008:administration & dosage* / Q000009:adverse effects*; D000077866:Clofarabine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy*; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced
D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D000077866:Clofarabine